复宏汉霖(02696)今日盘中大涨5.24%,主要由于该公司自主研发的抗PD-1单抗新药H药(商品名:汉斯状®)于2月5日正式获得欧盟委员会批准,用于广泛期小细胞肺癌成人患者的一线治疗,成为全球首个且唯一在欧盟获批用于广泛期小细胞肺癌治疗的抗PD-1单抗。
这标志着复宏汉霖在国际化进程中取得重大突破。H药在欧洲获批不仅填补了该领域的空白,还有望迅速抢占280亿美元的欧洲PD-(L)1市场份额。数据显示,H药已在中国、印尼、柬埔寨等30多个国家获批,并通过授权的方式将商业化权益扩展至70多个国家和地区。
除了H药,复宏汉霖还有多款产品在全球范围内取得进展,体现了其强大的全球化能力。公司建立了国际化产能体系和商业化布局,拥有完整的研发、供应链和销售团队,有望持续推动海外商业化成功。分析人士认为,市场高度认可复宏汉霖的国际化战略和长期成长,表现在此次H药获批后股价大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.